Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/sKdwhMrCDsauxBJlbY

November 10, 2009News for the biotech, medical device, drug and food regulatory profession
 
  Drugs & Biologics 
  • Trade group urges FDA safety seal for Web drug, device data
    The FDA should create a universal safety symbol certifying agency-approved data about drugs and medical devices on the Internet, a pharmaceutical trade group recommended. The proposal was issued ahead of a public meeting on how the FDA should handle social and online media promotion of medical products. Reuters (11/9) Email this Story
  Health Care in Transition 
  • Indian drug, biotech firms weigh pros, cons of U.S. health reform
    The health reform bill recently passed by House lawmakers could increase demand for generic drugs and boost the profit of generic drugmakers based in India, industry executives said. However, manufacturers of generic biotech drugs in India would also be adversely affected by a measure that gives brand-name biopharmaceutical firms 12 years of market protection. The Economic Times (India) (11/10) Email this Story
  • Device group urges House to tax firms based on FDA's product class
    The Advanced Medical Technology Association has urged the House to differentiate the proposed tax in a recently passed health reform bill based on the FDA's device classification "to recognize the diversity of medical device products and the thousands of companies that develop and manufacture them." AdvaMed has also called for an exemption from the proposed tax of device makers with an annual income of less than $100 million. Star Tribune (Minneapolis-St. Paul, Minn.) (11/9) Email this Story
  • Beckman CEO: Health reform to edge up demand for devices, tests
    Overhauling the U.S. health care system to expand insurance coverage would boost the demand for laboratory tests and medical devices by only 1% to 2% per year over the next 10 years because such a proposal would cover many young individuals who don't need regular treatment, said Beckman Coulter CEO Scott Garrett. Garrett said he hopes that a proposed tax on test and device makers would be lowered as lawmakers work to harmonize health reform measures in Congress. Reuters (11/9) Email this Story
  • Other News
  Biotechnology 
  • Rhode Island Hospital gets $11M grant for stem cell research center
    The NIH's National Center for Research Resources has awarded an $11 million grant to Rhode Island Hospital to help it set up a stem cell research facility that will focus on the use of adult stem cells in cell repair. The five-year grant will "help us to assemble a group of outstanding, talented investigators who excel in these areas," said Dr. Peter Quesenberry, the hospital's director of hematology/oncology. The Providence Journal (R.I.) (free registration) (11/10) Email this Story
  • U.K. scientists look at use of human material in animal experiments
    Scientists at U.K.'s Academy of Medical Sciences is set to launch a study today to examine the use of animals containing human DNA or organs in research and determine possible limitations of such experiments. "It sounds yucky, but it may be well worth doing if it's going to lead to a cure for something horrible," said Robin Lovell-Badge, a stem cell expert and member of the research team. Google/The Associated Press (11/9) Email this Story
  Food & Dietary Ingredients 
  Featured Content 
 

  Medical Devices 
  FDLI Items 
  • Monograph Series
     
    FDLI's Monograph Series is a groundbreaking set of six special reports specifically designed for attorneys, regulatory affairs and compliance specialists, manufacturers and consultants in the ever-changing food and drug field. The monographs are designed to provide you with inside information and proprietary analysis to enable you to advise your clients or help your company comply with vexing issues, regulations or guidance. View the titles. Purchase the series. Email this Story
  • A human resource recruitment tool
     
    FDLI's Job Board, in partnership with SmartBrief, offers members and nonmembers access to quality food and drug professionals. This service includes the opportunity to post job openings, view jobs posted, submit a resume, as well as view resumes posted. The Job Board is updated regularly as new submissions are received. While posting resumes is complimentary, only FDLI members can submit job postings for FREE. Email this Story
Learn more about FDLI ->About FDLI  |  Join FDLI  |  Conferences  |  Publications

Advertising Associate AttorneyManatt, Phelps & Phillips LLPWashington, DC
Health Policy Analyst and ProgrammerGenentechWashington, DC
Sr. Paralegal (Pharmaceutical Contracts/Transactions)Endo PharmaceuticalsChadds Ford, PA
Manager, Commercial Compliance - AuditingAmylin PharmaceuticalsSan Diego, CA
Account ManagerAlfa Laval, Inc.Omaha, NE

  SmartQuote 
Always forgive your enemies; nothing annoys them so much."
--Oscar Wilde,
Irish writer


 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Executive:  Chris Pope 202-737-5500 ext. 295
Job Board:  Lee Vanderwerff 202-737-5500 ext. 248
 
Read more at SmartBrief.com
A powerful Web site for SmartBrief readers including:
 
 
 Recent FDLI SmartBrief Issues:   Lead Editor:  Elizabeth Collins
     
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005
 
 
© 1999-2010 SmartBrief, Inc.® Legal Information